These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12819512)

  • 1. Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization.
    Robbins GK; Addo MM; Troung H; Rathod A; Habeeb K; Davis B; Heller H; Basgoz N; Walker BD; Rosenberg ES
    AIDS; 2003 May; 17(8):1121-6. PubMed ID: 12819512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: long-term follow-up.
    Levine AM; Groshen S; Allen J; Munson KM; Carlo DJ; Daigle AE; Ferre F; Jensen FC; Richieri SP; Trauger RJ; Parker JW; Salk PL; Salk J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(4):351-64. PubMed ID: 8601221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1-Specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated, gp120-depleted HIV-1 in incomplete Freund's adjuvant.
    Moss RB; Webb E; Giermakowska WK; Jensen FC; Savary JR; Wallace MR; Carlo DJ
    J Acquir Immune Defic Syndr; 2000 Jul; 24(3):264-9. PubMed ID: 10969351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected thai subjects with CD4-cell counts of >300.
    Churdboonchart V; Sakondhavat C; Kulpradist S; Na Ayudthya BI; Chandeying V; Rugpao S; Boonshuyar C; Sukeepaisarncharoen W; Sirawaraporn W; Carlo DJ; Moss R
    Clin Diagn Lab Immunol; 2000 Sep; 7(5):728-33. PubMed ID: 10973445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452).
    Autran B; Murphy RL; Costagliola D; Tubiana R; Clotet B; Gatell J; Staszewski S; Wincker N; Assoumou L; El-Habib R; Calvez V; Walker B; Katlama C;
    AIDS; 2008 Jul; 22(11):1313-22. PubMed ID: 18580611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gpl60 vaccine among adults with advanced HIV infection. Massachusetts gp160 Working Group.
    DeMaria A; Kunches L; Mayer K; Cohen C; Epstein P; Werner B; Day J; DeCristofaro J; Landers S; Tang Y; Coady W
    J Hum Virol; 2000; 3(4):182-92. PubMed ID: 10990166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-associated HIV-1 messenger RNA and DNA in T-helper cell and monocytes in asymptomatic HIV-1-infected subjects on HAART plus an inactivated HIV-1 immunogen.
    Patterson BK; Carlo DJ; Kaplan MH; Marecki M; Pawha S; Moss RB
    AIDS; 1999 Sep; 13(13):1607-11. PubMed ID: 10509560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization with an HIV-1 immunogen induces CD4+ and CD8+ HIV-1-specific polyfunctional responses in patients with chronic HIV-1 infection receiving antiretroviral therapy.
    Valor L; Navarro J; Carbone J; Rodríguez-Sáinz C; Gil J; López F; Fernández-Cruz E;
    Vaccine; 2008 May; 26(22):2738-45. PubMed ID: 18433946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. VaxSyn Protocol Team.
    Pontesilli O; Guerra EC; Ammassari A; Tomino C; Carlesimo M; Antinori A; Tamburrini E; Prozzo A; Seeber AC; Vella S; Ortona L; Aiuti F
    AIDS; 1998 Mar; 12(5):473-80. PubMed ID: 9543445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study.
    Harrer T; Plettenberg A; Arastéh K; Van Lunzen J; Fätkenheuer G; Jaeger H; Janssens M; Burny W; Collard A; Roman F; Loeliger A; Koutsoukos M; Bourguignon P; Lavreys L; Voss G
    Vaccine; 2014 May; 32(22):2657-65. PubMed ID: 24144472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects.
    Fernandez-Cruz E; Moreno S; Navarro J; Clotet B; Bouza E; Carbone J; Peña JM; Pérez Molina J; Podzamczer D; Rubio R; Ocaña I; Pulido F; Viciana P; Maradona JA; Blazquez R; Barros C; Quereda C; Rodriguez-Sainz C; Gil J; Abad ML; Díaz L; Cantó C; Muñoz MA; Ferrer E; Jou A; Sirera G; Díaz M; Lopez F; Gatell JM; Gonzalez-Lahoz J;
    Vaccine; 2004 Aug; 22(23-24):2966-73. PubMed ID: 15297045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946).
    Kundu-Raychaudhuri S; Sevin A; Kilgo P; Nokta M; Pollard RB; Merigan TC
    AIDS Res Hum Retroviruses; 2001 Oct; 17(15):1371-8. PubMed ID: 11679149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trial.
    Kahn JO; Cherng DW; Mayer K; Murray H; Lagakos S
    JAMA; 2000 Nov; 284(17):2193-202. PubMed ID: 11056590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs.
    Turner JL; Kostman JR; Aquino A; Wright D; Szabo S; Bidwell R; Goodgame J; Daigle A; Kelley E; Jensen F; Duffy C; Carlo D; Moss RB
    HIV Med; 2001 Apr; 2(2):68-77. PubMed ID: 11737381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative.
    Bartlett JA; Wasserman SS; Hicks CB; Dodge RT; Weinhold KJ; Tacket CO; Ketter N; Wittek AE; Palker TJ; Haynes BF
    AIDS; 1998 Jul; 12(11):1291-300. PubMed ID: 9708408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV).
    Boström AC; Hejdeman B; Matsuda R; Fredriksson M; Fredriksson EL; Bratt G; Sandström E; Wahren B
    Vaccine; 2004 Apr; 22(13-14):1683-91. PubMed ID: 15068851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators.
    Kelleher AD; Roggensack M; Jaramillo AB; Smith DE; Walker A; Gow I; McMurchie M; Harris J; Patou G; Cooper DA
    AIDS; 1998 Jan; 12(2):175-82. PubMed ID: 9468366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of HIV-1-infected Thai patients immunized with Remune monotherapy.
    Sukeepaisarncharoen W; Churdboonchart V; Kulpradist S; Isarangkura Na Ayudthya B; Rugpao S; Chandeying V; Sirawaraporn W; Carlo D; Moss RB
    HIV Clin Trials; 2001; 2(5):391-8. PubMed ID: 11673813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection.
    Kinloch-de Loes S; Hoen B; Smith DE; Autran B; Lampe FC; Phillips AN; Goh LE; Andersson J; Tsoukas C; Sonnerborg A; Tambussi G; Girard PM; Bloch M; Battegay M; Carter N; El Habib R; Theofan G; Cooper DA; Perrin L;
    J Infect Dis; 2005 Aug; 192(4):607-17. PubMed ID: 16028129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial. European Multinational IMMUNO AIDS Vaccine Study Group.
    Goebel FD; Mannhalter JW; Belshe RB; Eibl MM; Grob PJ; de Gruttola V; Griffiths PD; Erfle V; Kunschak M; Engl W
    AIDS; 1999 Aug; 13(12):1461-8. PubMed ID: 10465068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.